CroiValve

CroíValve is a medical device company developing a minimally invasive solution for severe Tricuspid Regurgitation (TR), a heart condition that affects millions worldwide. TR occurs when the tricuspid valve on the right side of the heart does not close properly, resulting in blood flowing backward and causing debilitating symptoms. CroíValve's DUO™ Tricuspid Coaptation Valve System is a novel approach that combines repair and replacement to provide a tailored solution for each patient. The company is based in Dublin, Ireland, and has a team of experienced professionals in clinical, technical, and commercial fields.

CroíValve has achieved significant milestones in its journey, including successful First in Human implants of its DUO system, securing FDA IDE approval and initiating clinical trials, and expanding its patent portfolio. They have garnered industry recognition through numerous awards and have secured significant funding rounds to support their research and development efforts. CroíValve aims to revolutionize the treatment of TR by providing a less invasive and more effective treatment option for patients.

CroíValve is an early-stage medical device company focused on developing a minimally invasive solution for severe tricuspid regurgitation (TR), a heart condition affecting millions. Recognizing the significant unmet need for effective treatment options, CroíValve is dedicated to providing a "Best-In-Class" solution that improves quality of life and reduces mortality for patients struggling with TR.

CroíValve fosters a collaborative and innovative culture focused on developing a minimally invasive solution for tricuspid regurgitation. They value strong clinical, technical, and commercial expertise, evident in their team's backgrounds and leadership roles. With a mission to improve patient lives, the company actively seeks out and celebrates breakthroughs in medical device technology, reflected in their numerous awards and successful clinical trials.